In This Article:
HACKENSACK, NJ / ACCESS Newswire / April 24, 2025 / Champions Oncology (NASDAQ:CSBR), a global leader in oncology R&D solutions, has announced a strategic collaboration with Turbine, the creators of the world's first interpretable cell simulation platform. This partnership is set to revolutionize biopharma drug discovery workflows by integrating Champions' state-of-the-art multi-omic dataset with Turbine's cutting-edge virtual lab technology.
By combining Champions' comprehensively annotated, clinically relevant multi-omic datasets with Turbine's virtual cell-based simulation platform and its capacity to generalize beyond training data, researchers can now conduct in silico experiments with exceptional speed and precision, covering perturbations they would otherwise be unable to investigate. This significant synergy minimizes reliance on traditional laboratory methods and enhances drug discovery initiatives, ranging from target identification to the generation of mechanistic insights, through the integration of highly translational multi-omics datasets.
"We're excited to partner with Turbine, a pioneer in predictive simulation technology," said Ronnie Morris, CEO of Champions Oncology. "By combining our unparalleled clinically relevant datasets with Turbine's powerful in silico platform, we're addressing key limitations in traditional R&D and accelerating the path to smarter, faster drug development. Together, we're redefining what's possible in precision oncology."
"This partnership underscores a core truth: the future of AI-driven drug discovery hinges on access to rich, clinically grounded datasets like those developed by Champions Oncology," said Matt Newman, EVP and General Manager of Champions' Data Platform. "By pairing our high quality multi-omic data with Turbine's cutting-edge simulation technology, we're equipping the industry to understand cancer biology at greater depths-and to accelerate R&D with unmatched precision, speed, and translational impact."
"When selecting a data partner, we looked for more than just molecular depth, we needed real-world translational relevance and ease of access. Champions Oncology offers a unique combination: deeply characterized samples paired with both in vivo experimental results and clinical outcome data from the same patients. That level of integration is simply unique in the market, and it's critical for training and validating simulations that aim to generalize to accurately predict unseen treatment responses in patients." said Daniel Veres, Co-founder & CSO at Turbine.